Citation

Lindenmayer JP, Kanellopoulou I. Psychiatr. Clin. North Am. 2009; 32(4): 885-902.

Affiliation

Department of Psychiatry, New York University School of Medicine, New York University, Wards Island, New York, NY 10035, USA; Psychopharmacology Research Unit, Nathan Kline Institute for Psychiatric Research, New York, NY, USA; Manhattan Psychiatric Cente

Copyright

(Copyright © 2009, Elsevier Publishing)

DOI

10.1016/j.psc.2009.08.006

PMID

19944890

Abstract

Impulsive and aggressive behaviors are important clinical challenges in the treatment of patients with schizophrenia. They occur both in the acute phase as well as in the chronic phase of the disorder and call for differentiated treatment interventions. It is important to always first consider behavioral and nonpharmacological interventions. High levels of structure and organization together with a nonconfrontational approach may be very successful interventions. In terms of acute pharmacological interventions, clinicians now have a broad spectrum of intramuscular antipsychotic compounds available with rapid onset of action and relatively little sedation. There is a need for new compounds with a more acceptable tolerability profile for the long-term treatment of these important syndromes.

Language: en